CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study

Tyrosine kinase inhibitors (TKIs) have greatly improved chronic myeloid leukemia (CML) treatments, with survival rates close to the general population. Yet, for the very elderly, robust data remains limited. This study focused on assessing comorbidities, treatment approaches, responses, and survival...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of hematology 2024-09, Vol.103 (9), p.3585-3594
Hauptverfasser:	Rozental, Alon, Halperin, Erez, Leibovitch, Chiya, Barzili, Meirav, Michowitz, Maya Koren, Duek, Adrian, Rozovski, Uri, Extermann, Martine, Raanani, Pia, Shacham-Abulafia, Adi
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Cancer therapies Clinical trials Comorbidity Diabetes Disease Hematology Leukemia Life expectancy Medical records Medicine Medicine & Public Health Older people Oncology Patients Population Risk factors Survival analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!